Cellvizio is a probe-based Confocal Laser Endomicroscopy (pCLE) system that provides physicians and researchers high-resolution cellular views of tissue inside the body.

The FDA cleared Cellvizio is designed to improve patient outcomes and reduce costs within a hospital.

It also obtained CE-Mark for use in the GI tract, biliary and pancreatic ducts and lungs and during fine needle aspiration procedures.

Apollo Gleneagles chief of gastroenterology Dr Mahesh Goenka said this is great news for patients.

"Optical Biopsy with Cellvizio can now be used to improve patient management in several key gastroenterological indications and I am proud to be the first doctor in India to provide such advanced care, "Dr Goenka added.

Apollo Gleneagles Hospitals is a joint venture of Apollo Group of Hospitals, India and Parkway Health of Singapore.

Mauna Kea Technologies CEO and founder Sacha Loiseau said the company continues to make strong progress in its Asia-Pacific development and this first prestigious installation in India is another milestone in this high-growth region.

"We look forward to working with the Apollo Hospitals Group to improve patient care throughout the subcontinent," Loiseau added.